All In MedTech

FDA Clearance Tracker · P990009-S013

FLOSEAL HEMOSTATIC MATRIX

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 10, 2005 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 10, 2005

Approved

Time to decision

843 days

Received Nov 18, 2002. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990009-S013
Device name
FLOSEAL HEMOSTATIC MATRIX
Applicant location
Round Lake, IL
Received
Nov 18, 2002
Decided
Mar 10, 2005
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990009

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code LMF

FDA's approval statement

As written in FDA's record.

APPROVAL FOR AN ALTERNATE KIT CONFIGURATION THAT CONTAINS A HUMAN THROMBIN COMPONENT. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME FLOSEAL HEMOSTATIC MATRIX AND IS INDICATED FOR USE IN SURGICAL PROCEDURES (OTHER THAN IN OPHTHALMIC) AS AN ADJUNCT TO HEMOSTASIS WHEN CONTROL OF BLEEDING BY LIGATURE OR CONVENTIONAL PROCEDURES IS INEFFECTIVE OR IMPRACTICAL.

Source documents

Other decisions for Baxter Healthcare Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.